Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
$1.75
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.75
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$1.56 - $26.05
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$47.01M
Enterprise Value-$9.60M
Total Cash (Recent Filing)$50.90M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Mar 10, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding27,984,040
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.06
Price to Sales (P/S)0.00
P/FCF Ratio-4.94
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$9.25Price Target Upside428.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyBriquilimab has shown robust efficacy with clean safety across different studies, providing a consistently solid profile.
Financial StabilityThe $51M on the balance sheet provides runway through the first half of 2026, with additional funding options for the planned Ph2b CSU study.
Partnership OpportunitiesManagement continues to get inbound interest on briquilimab, indicating potential for a clinical co-development option with a partner.
Bears Say
Competitive DisadvantageThe expected start for the Ph2b CSU study has now been pushed out to mid-'26, placing Jasper ~18-24 months behind the competition.
Operational ChallengesA strategic shift has led to a corporate restructuring, including a 50% workforce reduction and a new interim CMO, to fully concentrate resources on urticaria.
Trial DelaysJSPR has taken a more careful approach to patient enrollment in BEACON, slowing the pace of the enrollment and shifting the timing of the BEACON update.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $1.56 and its highest was $26.05 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $47.01M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 103 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.085.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.72.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,984,040 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.13 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.25 (428.57% Upside)
$9.25 (428.57% Upside)
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $347.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.39%
12-Months-Change
Fundamentals
Return on Equity
-191.12%
Trailing 12-Months
Asset Growth
-42.19%
Trailing 12-Months
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$9.25
▲(428.57% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
4.36% Mutual Funds
48.89% Other Institutional Investors
39.64% Public Companies and Individual Investors